Scandinavian Tobacco Group (STG) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Q2 2025 net sales were DKK 2,361 million, nearly flat year-over-year, with organic net sales down 4.1% due to discontinued ZYN distribution and lower contract manufacturing sales; Mac Baren acquisition supported growth.
All three core product categories returned to growth in Q2, reversing Q1 declines, but Next Generation Products saw a -43% organic decline due to ZYN exit; XQS brand delivered double-digit growth.
EBITDA margin fell to 21.1% from 24.5% last year, mainly due to product mix, ZYN exit, and investments in nicotine pouches and market positions.
Mac Baren integration is on track, targeting DKK 150 million in synergies by 2027, and growth enablers like U.S. retail and XQS pouches now represent 10% of group net sales.
ERP system rollout (SAP S/4HANA) continues as planned, with manageable operational issues.
Financial highlights
Q2 2025 net sales: DKK 2,361 million (-0.2% YoY); organic net sales growth: -4.1%; Mac Baren added 7% to growth, FX -3%.
EBITDA before special items: DKK 499 million (margin 21.1%), down from DKK 580 million (24.5%) in Q2 2024.
Net profit: DKK 227 million in Q2; adjusted EPS: DKK 3.3, down from DKK 4.1 in Q2 2024.
Free cash flow before acquisitions: DKK 119 million (Q2 2024: DKK 177 million); full-year guidance of DKK 800 million–1 billion reaffirmed.
Leverage ratio increased to 2.9x from 2.6x at end 2024, mainly due to dividend payments.
Outlook and guidance
Full-year 2025 net sales expected at DKK 9.1–9.5 billion, likely at the lower end due to FX; EBITDA margin guidance maintained at 18–22%.
Free cash flow before acquisitions expected at DKK 0.8–1.0 billion; adjusted EPS guidance: DKK 10–13.
Positive organic net sales growth anticipated in H2, supported by new U.S. retail stores, XQS growth, and stabilized market shares.
Guidance assumes no new acquisitions and current exchange rates; a 10% USD/DKK change would impact net sales by ~5 percentage points.
Uncertainties remain high, especially regarding U.S. dollar sensitivity and U.S. handmade cigar consumption.
Latest events from Scandinavian Tobacco Group
- Organic sales fell 8.8% in Q1 2025, prompting lower guidance amid US and FX headwinds.STG
Q1 202513 Mar 2026 - 2025 results declined, but Focus2030 and strong cash flow support a stable 2026 outlook.STG
Q4 20259 Mar 2026 - Focus2030 targets growth in cigars and nicotine pouches, efficiency, and flexible shareholder returns.STG
CMD 20253 Feb 2026 - Q2 2024 saw 6.3% sales growth, margin gains, and a strategic acquisition for future expansion.STG
Q2 202423 Jan 2026 - Q3 net sales up 7.1% on Mac Baren deal; margin and organic growth declined.STG
Q3 202414 Jan 2026 - Net sales up 5.4% to DKK 9.2bn, but profit down 20.5% amid margin pressure and investments.STG
Q4 202426 Dec 2025 - Record sales, higher dividends, and all board proposals approved amid ongoing strategic investments.STG
AGM 202529 Nov 2025 - Q3 2025 organic sales rose 0.3% with margin recovery and narrowed full-year guidance.STG
Q3 202512 Nov 2025